Evotec SE (EVOTF) 股价，以美元计价

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including BoehringerIngelheim, CHDI, Genentech, Medimmune/AstraZeneca, Novartis and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and preclinical development. These include partnerships with Boehringer Ingelheim, MedImmune and with Andromeda (Teva) in the field of diabetes and with Roche in the field of Alzheimer's disease. Evotec is built on integrated drug discovery know-how of more than 15 years and is a leading player in the drug discovery field. The Company’s headquarters are located in Hamburg, Germany. Additional major operations are based in Abingdon, UK, Göttingen, Munich, Germany, Thane, India and San Francisco, USA. Evotec has more than 600 employees worldwide.